We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
METOCLOPRAMIDE DEMOGEN (Demogen Australia Pty Ltd trading as DEMOGEN Pharmaceuticals)
Product name
METOCLOPRAMIDE DEMOGEN
Date registered
Evaluation commenced
Decision date
Approval time
136 (255 working days)
Active ingredients
metoclopramide hydrochloride monohydrate
Registration type
New generic medicine
Indication
Adults (20 years and over)
- Relief of nausea and vomiting associated with migraine, cancer therapy (chemotherapy orradiation), malignant disease, labour, infectious disease and uraemia
- Control of post-operative vomiting
- Assist in small bowel intubation
Metoclopramide is of little benefit for the prevention or treatment of motion sickness.
Young Adults and Children (over 1 year of age)
Metoclopramide should be restricted to the following conditions and only used as second line therapy, when used to treat children and young adults under 20 years of age because of the risk of adverse effects:
- Severe intractable vomiting of known cause
- Vomiting associated with radiation therapy or intolerance to cytotoxic drugs
- Assist in small bowel intubation